Elm City Gun Club Group

Researchers have developed a novel class of non-opioid compounds that inhibit the ENT1 transporter. By inhibiting this transporter, the body elevates its natural concentration of adenosine, which acts as a powerful endogenous pain suppressor.

Unlike opioids, where the body builds up a tolerance, animal models in 2026 have shown that the effectiveness of ENT1 inhibitors actually increases with repeated administration. This "accumulation of action" makes them an ideal candidate for chronic neuropathic pain management.